The present invention provides a compound which is represented by the following structure: which inhibits, regulates and/or modulates kinase receptors, particularly c-Met, KDR, c-Kit, flt-3 and flt-4. This compound is therefore suitable for the treatment of diseases or disorders associated with uncontrolled, abnormal and/or unwanted cellular activities.
